FINNENCE ▪ THE WIRE FILE
THE WIRE · № 70982
News■ Unclear/unknown
Cyrano Therapeutics' Phase 2 FLAVOR Trial Selected to Open 72nd Annual Meeting of the American Rhinologic Society (ARS)
KINDNews
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN2026-10-08 12:10 UTC
LAST UPDATE2026-10-08 12:10 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
A conference slot for a private biotech's Phase 2 results is not a public-market catalyst.
Clinical-stage private biotech, no ticker exposure
CATALYST TO WATCH
Phase 2 FLAVOR trial data disclosure
MAIN RISK
Private company, early data, unlisted
FULL DISPATCH
DELRAY BEACH, Fla., Oct. 8, 2026 /PRNewswire/ -- Cyrano Therapeutics, Inc., a clinical-stage regenerative medicine company developing novel treatments for smell and taste disorders, today announced that results from the Phase 2 FLAVOR trial of CYR-064 will open the General Session at the...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
Vocca raises $20M after growing from 2,000 to 15,000 medical practitioners in a year2026-10-08 12:12 UTC
Vocca raises $20M after growing from 2,000 to 15,000 medical practitioners in a year2026-10-08 12:12 UTC
→CORRELATIONshares Healthcare
Vinci Pharmaceuticals Inc. Closes More Than $8 Million Series A Financing to Advance EPIPLANT™ Drug Delivery Platform2026-10-08 12:13 UTC
Vinci Pharmaceuticals Inc. Closes More Than $8 Million Series A Financing to Advance EPIPLANT™ Drug Delivery Platform2026-10-08 12:13 UTC
→CORRELATIONshares Healthcare
Psilera Greenlit to Initiate Phase 2 of NIH Grant for Alcohol Use Disorder2026-10-08 12:15 UTC
Psilera Greenlit to Initiate Phase 2 of NIH Grant for Alcohol Use Disorder2026-10-08 12:15 UTC
→CORRELATIONshares Healthcare
GLP-1s could offer unexpected relief from back and knee pain, but doctors urge caution2026-10-08 12:30 UTC
GLP-1s could offer unexpected relief from back and knee pain, but doctors urge caution2026-10-08 12:30 UTC
←CORRELATIONshares Healthcare
Shoulder Innovations Initiates Commercial Launch of the InSet® Go2026-10-08 11:00 UTC
Shoulder Innovations Initiates Commercial Launch of the InSet® Go2026-10-08 11:00 UTC
←CORRELATIONshares Healthcare
Nuevocor Doses First Patient in SUNBEAM-LMNA Phase 1/2 Trial and Receives FDA Fast Track Designation for NVC-001 in LMNA Dilated Cardiomyopathy2026-10-08 11:30 UTC
Nuevocor Doses First Patient in SUNBEAM-LMNA Phase 1/2 Trial and Receives FDA Fast Track Designation for NVC-001 in LMNA Dilated Cardiomyopathy2026-10-08 11:30 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.